Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Trulicity 0.75 mg solution for injection in pre-filled pen.
Trulicity 1.5 mg solution for injection in pre-filled pen.
Trulicity 3 mg solution for injection in pre-filled pen.
Trulicity 4.5 mg solution for injection in pre-filled pen.
| Pharmaceutical Form |
|---|
|
Solution for injection (injection). Clear, colourless solution. |
Trulicity 0.75 mg solution for injection in pre-filled pen: Each pre-filled pen contains 0.75 mg of dulaglutide* in 0.5 ml solution.
Trulicity 1.5 mg solution for injection in pre-filled pen: Each pre-filled pen contains 1.5 mg of dulaglutide* in 0.5 ml solution.
Trulicity 3 mg solution for injection in pre-filled pen: Each pre-filled pen contains 3 mg of dulaglutide* in 0.5 ml solution.
Trulicity 4.5 mg solution for injection in pre-filled pen: Each pre-filled pen contains 4.5 mg of dulaglutide* in 0.5 ml solution.
* produced in CHO cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. Dulaglutide exhibits several antihyperglycaemic actions of GLP-1. In the presence of elevated glucose concentrations, dulaglutide increases intracellular cyclic AMP (cAMP) in pancreatic beta cells leading to insulin release. Dulaglutide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes. |
| List of Excipients |
|---|
|
Sodium citrate |
Glass syringe (type I) encased in a disposable pen.
Each pre-filled pen contains 0.5 ml of solution.
Packs of 2 and 4 pre-filled pens and multipack of 12 (3 packs of 4) pre-filled pens. Not all pack sizes may be marketed.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
EU/1/14/956/001
EU/1/14/956/002
EU/1/14/956/003
EU/1/14/956/006
EU/1/14/956/007
EU/1/14/956/008
EU/1/14/956/011
EU/1/14/956/012
EU/1/14/956/013
EU/1/14/956/014
EU/1/14/956/015
EU/1/14/956/016
Date of first authorisation: 21 November 2014
Date of latest renewal: 23 August 2019
| Drug | Countries | |
|---|---|---|
| TRULICITY | Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.